EFEITO DOS PROBIÓTICOS SOBRE AS FUNÇÕES COGNITIVAS E MNEMÔNICAS DE PACIENTES COM DOENÇA DE ALZHEIMER

Autores

  • Cibelle Aparecida Felix Gonçalves Autor
  • Adrielly Regina Dantas Gomes Autor
  • Nayron Micael da Silva Santos Autor
  • Clarice da Silva Costa Autor
  • Iana Bantim Felício Calou Autor

DOI:

https://doi.org/10.56238/ERR01v10n4-046

Palavras-chave:

Doença de Alzheimer, Probióticos, Cognição

Resumo

A Doença de Alzheimer é uma patologia neurodegenerativa que afeta principalmente o sistema nervoso central, em especial dos idosos. Recentemente, o papel da microbiota intestinal na fisiopatologia e desenvolvimento de neurodegeneração vem sendo discutido. Em idosos há uma significativa modificação do microbioma intestinal e essa pode propiciar perda de funcionalidades e maior suscetibilidade a infecções gastrointestinais e a formação de produtos bacterianos como amilóides bacterianos e lipopolissacarídeos, que ativam cascata imune que leva a neuroinflamação e amplificação do processo neurodegenerativo. Diante desse cenário, o consumo de probióticos,tem se mostrado um importante aliado para o tratamento da disbiose e indiretamente das condições patológicas comuns da DA. Assim, o objetivo desta revisão é  avaliar sistematicamente a eficácia dos probióticos na melhora dos sintomas cognitivos e mnemônicos em pacientes com Alzheimer, além de observar padrões de doses e cepas nos estudos.  Esse trabalho trata-se de uma revisão do tipo sistemática, que após o processo de triagem, cinco artigos preencheram os critérios de inclusão. Os estudos analisados utilizaram diversos tipos de cepas, principalmente Lactobacillus e bifidobacterium, mas em várias formas de administração como cápsulas, suspensões e produtos lácteos. Os resultados não foram concordantes entre si, e apenas dois dos estudos encontraram melhoras cognitivas. A análise do risco de viés demonstrou falta de robustez e metodologia clara na execução dos estudos. Assim, apesar de parecerem promissores, a ausência de evidências sólidas e o grande número de vieses fazem com que os dados sejam inconclusivos e não confiáveis.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

AGAHI, Azadeh et al. Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial. Frontiers in Neurology, v. 9, 15 ago. 2018. Disponível em: https://doi.org/10.3389/fneur.2018.00662. Acesso em: 28 mar. 2025.

AKBARI, Elmira et al. Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. Frontiers in Aging Neuroscience, v. 8, 10 nov. 2016. Disponível em: https://doi.org/10.3389/fnagi.2016.00256. Acesso em: 28 mar. 2025.

BANIK, Avijit; BROWN, Richard E.; BAMBURG, James; et al. Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome? Journal of Alzheimer’s Disease, v. 47, n. 4, p. 815–843, 2015. Disponível em: https://journals.sagepub.com/doi/10.3233/JAD-150136. Acesso em: 30 ago. 2025.

BAZANELLA, Monika; MAIER, Tanja V; CLAVEL, Thomas; et al. Randomized controlled trial on the impact of early-life intervention with bifidobacteria on the healthy infant fecal microbiota and metabolome. The American Journal of Clinical Nutrition, v. 106, n. 5, p. 1274–1286, 2017. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0002916522026703. Acesso em: 30 ago. 2025.

BUFFIE, Charlie G.; PAMER, Eric G. Microbiota-mediated colonization resistance against intestinal pathogens. Nature Reviews. Immunology, v. 13, n. 11, p. 790–801, 2013. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC4194195/. Acesso em: 30 ago. 2025.

CHEN, Chun; AHN, Eun Hee; KANG, Seong Su; et al. Gut dysbiosis contributes to amyloid pathology, associated with C/EBPβ/AEP signaling activation in Alzheimer’s disease mouse model. Science Advances, v. 6, n. 31, p. eaba0466, 2020. Disponível em: https://www.science.org/doi/10.1126/sciadv.aba0466. Acesso em: 29 ago. 2025.

CHEN, Xinxin; YOU, Jiuhong; MA, Hui; et al. Transcranial pulse stimulation in Alzheimer’s disease. CNS Neuroscience & Therapeutics, v. 30, n. 2, p. e14372, 2023. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10848065/. Acesso em: 29 ago. 2025.

COSTEA, Paul I.; ZELLER, Georg; SUNAGAWA, Shinichi; et al. Towards standards for human fecal sample processing in metagenomic studies. Nature Biotechnology, v. 35, n. 11, p. 1069–1076, 2017. Disponível em:https://www.nature.com/articles/nbt.3960. Acesso em: 30 ago. 2025.

CUMMINGS, Jeffrey L.; MORSTORF, Travis; ZHONG, Kate. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer’s Research & Therapy, v. 6, n. 4, p. 37, 2014.Disponível em: https://alzres.biomedcentral.com/articles/10.1186/alzrt269. Acesso em: 29 ago. 2025.

CUMMINGS, Jeffrey; OSSE, Amanda M. Leisgang; CAMMANN, Davis; et al. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease. Biodrugs, v. 38, n. 1, p. 5–22, 2024. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789674/. Acesso em: 29 ago. 2025.

DI VINCENZO, Federica et al. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Internal and Emergency Medicine, 28 jul. 2023. Disponível em: https://doi.org/10.1007/s11739-023-03374-w. Acesso em: 13 mar. 2025.

DRUMMOND, Eleanor; WISNIEWSKI, Thomas. Alzheimer’s disease: experimental models and reality. Acta Neuropathologica, v. 133, n. 2, p. 155–175, 2017. Disponível em: http://link.springer.com/10.1007/s00401-016-1662-x. Acesso em: 30 ago. 2025.

ERATNE, Dhamidhu et al. Alzheimer’s disease: clinical update on epidemiology, pathophysiology and diagnosis. Australasian Psychiatry, v. 26, n. 4, p. 347-357, 3 abr. 2018. Disponível em: https://doi.org/10.1177/1039856218762308. Acesso em: 14 mar. 2025.

FASNACHT, Jael S.; WUEEST, Alexandra S.; BERRES, Manfred; et al. Conversion between the Montreal Cognitive Assessment and the MINI‐MENTAL Status Examination. Journal of the American Geriatrics Society, v. 71, n. 3, p. 869–879, 2023. Disponível em: https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18124. Acesso em: 29 ago. 2025.

FAULIN, Tanize do Espirito Santo; ESTADELLA, Debora. ALZHEIMER’S DISEASE AND ITS RELATIONSHIP WITH THE MICROBIOTA-GUT-BRAIN AXIS. Arquivos de Gastroenterologia, v. 60, n. 1, p. 144-154, jan. 2023. Disponível em: https://doi.org/10.1590/s0004-2803.202301000-17. Acesso em: 13 mar. 2025.

FERREIRO, Aura L.; CHOI, JooHee; RYOU, Jian; et al. Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease. Science Translational Medicine, v. 15, n. 700, p. eabo2984, 2023. Disponível em:https://www.science.org/doi/10.1126/scitranslmed.abo2984. Acesso em: 30 ago. 2025.

FREEDMAN, Stephen B.; SCHNADOWER, David; TARR, Phillip I. The Probiotic Conundrum: Regulatory Confusion, Conflicting Studies, and Safety Concerns. JAMA, v. 323, n. 9, p. 823, 2020. Disponível em: https://jamanetwork.com/journals/jama/fullarticle/2762317. Acesso em: 30 ago. 2025.

GRABHER, Barbara J. Effects of Alzheimer Disease on Patients and Their Family. Journal of Nuclear Medicine Technology, v. 46, n. 4, p. 335-340, 23 ago. 2018. Disponível em: https://doi.org/10.2967/jnmt.118.218057. Acesso em: 13 mar. 2025.

HASAN, Nihal; YANG, Hongyi. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ, v. 7, p. e7502, 2019. Disponível em:https://peerj.com/articles/7502. Acesso em: 29 ago. 2025.

HIGGINS, JPT et al. (editores). Cochrane Handbook for Systematic Reviews of Interventions versão 6.2 (atualizado em fevereiro de 2021). Cochrane, 2021. Disponível em www.training.cochrane.org/handbook Acesso em: 29 mar. 2025.

HILL, Colin; GUARNER, Francisco; REID, Gregor; et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews. Gastroenterology & Hepatology, v. 11, n. 8, p. 506–514, 2014.

HSU, Yu-Chieh et al. Efficacy of Probiotic Supplements on Brain-Derived Neurotrophic Factor, Inflammatory Biomarkers, Oxidative Stress and Cognitive Function in Patients with Alzheimer’s Dementia: A 12-Week Randomized, Double-Blind Active-Controlled Study. Nutrients, v. 16, n. 1, p. 16, 20 dez. 2023. Disponível em: https://doi.org/10.3390/nu16010016. Acesso em: 28 mar. 2025.

JAIN, Arpit; MADKAN, Suryansh; PATIL, Praful. The Role of Gut Microbiota in Neurodegenerative Diseases: Current Insights and Therapeutic Implications. Cureus, v. 15, n. 10, p. e47861. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680305/. Acesso em: 30 ago. 2025.

JANDHYALA, Sai Manasa; TALUKDAR, Rupjyoti; SUBRAMANYAM, Chivkula; et al. Role of the normal gut microbiota. World Journal of Gastroenterology, v. 21, n. 29, p. 8787–8803, 2015. Disponível em: https://www.wjgnet.com/1007-9327/full/v21/i29/8787.htm/. Acesso em: 30 ago. 2025.

KCIUK, Mateusz; KRUCZKOWSKA, Weronika; GAŁĘZIEWSKA, Julia; et al. Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications. International Journal of Molecular Sciences, v. 25, n. 22, p. 11955, 2024. Disponível em: https://www.mdpi.com/1422-0067/25/22/11955. Acesso em: 29 ago. 2025.

KENT, Sarah A.; SPIRES-JONES, Tara L.; DURRANT, Claire S. The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics. Acta Neuropathologica, v. 140, n. 4, p. 417-447, 29 jul. 2020. Disponível em: https://doi.org/10.1007/s00401-020-02196-w. Acesso em: 13 mar. 2025.

KESIKA, Periyanaina et al. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease. Life Sciences, v. 264, p. 118627, jan. 2021. Disponível em: https://doi.org/10.1016/j.lfs.2020.118627. Acesso em: 23 mar. 2025.

KECHAGIA, Maria; BASOULIS, Dimitrios; KONSTANTOPOULOU, Stavroula; et al. Health Benefits of Probiotics: A Review. ISRN Nutrition, v. 2013, p. 481651, 2013. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045285/. Acesso em: 29 ago. 2025.

KNOPMAN, David S. et al. Alzheimer disease. Nature Reviews Disease Primers, v. 7, n. 1, 13 maio 2021. Disponível em: https://doi.org/10.1038/s41572-021-00269-y. Acesso em: 13 mar. 2025.

KÖHLER, Cristiano et al. The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease. Current Pharmaceutical Design, v. 22, n. 40, p. 6152-6166, 14 dez. 2016. Disponível em: https://doi.org/10.2174/1381612822666160907093807. Acesso em: 14 mar. 2025.

KRISTENSEN, Nadja B.; BRYRUP, Thomas; ALLIN, Kristine H.; et al. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Medicine, v. 8, n. 1, p. 52, 2016. Disponível em: https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-016-0300-5. Acesso em: 30 ago. 2025.

LAHTI, Leo; SALONEN, Anne; KEKKONEN, Riina A.; et al. Associations between the human intestinal microbiota, Lactobacillus rhamnosus GG and serum lipids indicated by integrated analysis of high-throughput profiling data. PeerJ, v. 1, p. e32, 2013. Disponível em: https://peerj.com/articles/32/. Acesso em: 30 ago. 2025.

LLORÉNS-RICO, Verónica; VIEIRA-SILVA, Sara; GONÇALVES, Pedro J.; et al. Benchmarking microbiome transformations favors experimental quantitative approaches to address compositionality and sampling depth biases. Nature Communications, v. 12, n. 1, p. 3562, 2021. Disponível em: https://www.nature.com/articles/s41467-021-23821-6. Acesso em: 30 ago. 2025.

LAURSEN, Martin Frederik; LAURSEN, Rikke Pilmann; LARNKJÆR, Anni; et al. Administration of two probiotic strains during early childhood does not affect the endogenous gut microbiota composition despite probiotic proliferation. BMC Microbiology, v. 17, n. 1, p. 175, 2017. Disponível em: http://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-017-1090-7. Acesso em: 30 ago. 2025.

LEBLHUBER, Friedrich et al. Probiotic Supplementation in Patients with Alzheimer’s Dementia - An Explorative Intervention Study. Current Alzheimer Research, v. 15, n. 12, p. 1106-1113, 28 set. 2018. Disponível em: https://doi.org/10.2174/1389200219666180813144834. Acesso em: 28 mar. 2025.

LEE, Hae-Ji; LEE, Kyung-Eon; KIM, Jeon-Kyung; et al. Suppression of gut dysbiosis by Bifidobacterium longum alleviates cognitive decline in 5XFAD transgenic and aged mice. Scientific Reports, v. 9, n. 1, p. 11814, 2019. Disponível em: https://www.nature.com/articles/s41598-019-48342-7. Acesso em: 29 ago. 2025.

LEKCHAND DASRIYA, Vaishali et al. Etiology and management of Alzheimer’s disease: Potential role of gut microbiota modulation with probiotics supplementation. Journal of Food Biochemistry, v. 46, n. 1, 19 dez. 2021. Disponível em: https://doi.org/10.1111/jfbc.14043. Acesso em: 13 mar. 2025.

LIU, Shan et al. Gut Microbiota and Dysbiosis in Alzheimer’s Disease: Implications for Pathogenesis and Treatment. Molecular Neurobiology, v. 57, n. 12, p. 5026-5043, 23 ago. 2020. Disponível em: https://doi.org/10.1007/s12035-020-02073-3. Acesso em: 13 mar. 2025.

LIU, Ping et al. Altered microbiomes distinguish Alzheimer’s disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain, Behavior, and Immunity, v. 80, p. 633-643, ago. 2019. Disponível em: https://doi.org/10.1016/j.bbi.2019.05.008. Acesso em: 14 mar. 2025.

LOH, Jian Sheng; MAK, Wen Qi; TAN, Li Kar Stella; et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduction and Targeted Therapy, v. 9, n. 1, p. 37, 2024. Disponível em: https://www.nature.com/articles/s41392-024-01743-1. Acesso em: 29 ago. 2025.

LYTHGOE, Mark P.; JENEI, Kristina; PRASAD, Vinay. Regulatory decisions diverge over aducanumab for Alzheimer’s disease. BMJ, p. e069780, 28 jan. 2022. Disponível em: https://doi.org/10.1136/bmj-2021-069780. Acesso em: 14 mar. 2025.

MAGHINI, Dylan G.; DVORAK, Mai; DAHLEN, Alex; et al. Quantifying bias introduced by sample collection in relative and absolute microbiome measurements. Nature Biotechnology, v. 42, n. 2, p. 328–338, 2024. Disponível em: https://www.nature.com/articles/s41587-023-01754-3. Acesso em: 30 ago. 2025.

MANCUSO, Cesare; SANTANGELO, Rosaria. Alzheimer’s disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence. Pharmacological Research, v. 129, p. 329–336, 2018. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S1043661817315748. Acesso em: 29 ago. 2025.

MARCHESI, Julian R.; ADAMS, David H.; FAVA, Francesca; et al. The gut microbiota and host health: a new clinical frontier. Gut, v. 65, n. 2, p. 330–339, 2016. Disponível em: https://gut.bmj.com/lookup/pmidlookup?view=long&pmid=26338727. Acesso em: 29 ago. 2025.

MENGHANI, Yash R. et al. A Review: Pharmacological and herbal remedies in The Management of Neurodegenerative disorder (Alzheimer’s). International Journal of Pharmacognosy and Life Science, v. 2, n. 1, p. 18-27, 1 jan. 2021. Disponível em: https://doi.org/10.33545/27072827.2021.v2.i1a.23. Acesso em: 13 mar. 2025.

MIOLA, Anna Carolina; ESPÓSITO, Ana Cláudia Cavalcante; MIOT, Hélio Amante. Técnicas de randomização e alocação para estudos clínicos. Jornal Vascular Brasileiro, v. 23, p. e20240046, 2024. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-54492024000100404&tlng=pt. Acesso em: 30 ago. 2025.

MONAGHAN, Thomas F.; AGUDELO, Christina W.; RAHMAN, Syed N.; et al. Blinding in Clinical Trials: Seeing the Big Picture. Medicina, v. 57, n. 7, p. 647, 2021. Disponível em: https://www.mdpi.com/1648-9144/57/7/647. Acesso em: 30 ago. 2025.

MOUSA, Walaa K.; CHEHADEH, Fadia; HUSBAND, Shannon. Microbial dysbiosis in the gut drives systemic autoimmune diseases. Frontiers in Immunology, v. 13, p. 906258, 2022. Disponível em: https://www.frontiersin.org/articles/10.3389/fimmu.2022.906258/full. Acesso em: 29 ago. 2025.

NISHIDA, Atsushi et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clinical Journal of Gastroenterology, v. 11, n. 1, p. 1-10, 29 dez. 2017. Disponível em: https://doi.org/10.1007/s12328-017-0813-5. Acesso em: 13 mar. 2025.

OJHA, Sandhya; PATIL, Nil; JAIN, Mukul; et al. Probiotics for Neurodegenerative Diseases: A Systemic Review. Microorganisms, v. 11, n. 4, p. 1083, 2023. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140855/. Acesso em: 29 ago. 2025.

OUZZANI, Mourad et al. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews, v. 5, n. 1, dez. 2016. Disponível em: https://doi.org/10.1186/s13643-016-0384-4. Acesso em: 29 mar. 2025.

PEREIRA, Tamires dos Reis Santos. POTENCIAL TERAPÊUTICO DOS PROBIÓTICOS NA DOENÇA DE ALZHEIMER. 2022. Dissertação de mestrado — Universidade Federal da Bahia, Salvador, 2022. Disponível em: https://pgalimentos.ufba.br/sites/pgalimentos.ufba.br/files/tamires_dos_reis_santos_pereira.pdf. Acesso em: 13 mar. 2025.

RAMANAN, Vijay K.; ARMSTRONG, Melissa J.; CHOUDHURY, Parichita; et al. Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology. Neurology, v. 101, n. 19, p. 842–852, 2023. Disponível em: <https://www.neurology.org/doi/10.1212/WNL.0000000000207757>. Acesso em: 29 ago. 2025.

ROSA, Janaína Carla Parizotto da et al. Avaliação da microbiota intestinal e uso de probióticos na doença de Alzheimer. Debates em Psiquiatria, v. 14, p. 1-20, 31 dez. 2024. Disponível em: https://doi.org/10.25118/2763-9037.2024.v14.1346. Acesso em: 14 mar. 2025.

ROSSELLI, Mónica; URIBE, Idaly Vélez; AHNE, Emily; et al. Culture, Ethnicity, and Level of Education in Alzheimer’s Disease. Neurotherapeutics, v. 19, n. 1, p. 26–54, 2022. Disponível em: <https://linkinghub.elsevier.com/retrieve/pii/S1878747923001526>. Acesso em: 30 ago. 2025.

SCHILLING, Lucas Porcello; BALTHAZAR, Marcio Luiz Figueredo; RADANOVIC, Márcia; et al. Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dementia & Neuropsychologia, v. 16, n. 3 suppl 1, p. 25–39, 2022. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1980-57642022000400025&tlng=pt. Acesso em: 29 ago. 2025.

SHEN, Yao; FAN, Nairui; MA, Shu‐xia; et al. Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy. MedComm, v. 6, n. 5, p. e70168, 2025. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/mco2.70168. Acesso em: 30 ago. 2025.

SIERRA, Saleta; LARA-VILLOSLADA, Federico; SEMPERE, Lluis; et al. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe, v. 16, n. 3, p. 195–200, 2010. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S1075996410000181. Acesso em: 30 ago. 2025.

ŚLIŻEWSKA, Katarzyna; MARKOWIAK-KOPEĆ, Paulina; ŚLIŻEWSKA, Weronika. The Role of Probiotics in Cancer Prevention. Cancers, v. 13, n. 1, p. 20, 2020. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793079/. Acesso em: 29 ago. 2025.

TENCHOV, Rumiana; SASSO, Janet M.; ZHOU, Qiongqiong Angela. Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline. ACS Chemical Neuroscience, v. 15, n. 21, p. 3800–3827, 2024. Disponível em: https://pubs.acs.org/doi/10.1021/acschemneuro.4c00339. Acesso em: 29 ago. 2025.

TON, Alyne Mendonça Marques et al. Oxidative Stress and Dementia in Alzheimer’s Patients: Effects of Synbiotic Supplementation. Oxidative Medicine and Cellular Longevity, v. 2020, p. 1-14, 13 jan. 2020. Disponível em: https://doi.org/10.1155/2020/2638703. Acesso em: 28 mar. 2025.

VAN OLST, Lynn; ROKS, Sigrid J. M.; KAMERMANS, Alwin; et al. Contribution of Gut Microbiota to Immunological Changes in Alzheimer’s Disease. Frontiers in Immunology, v. 12, p. 683068, 2021.

WANG, Chongxin; NAGATA, Satoru; ASAHARA, Takashi; et al. Intestinal Microbiota Profiles of Healthy Pre-School and School-Age Children and Effects of Probiotic Supplementation. Annals of Nutrition and Metabolism, v. 67, n. 4, p. 257–266, 2015. Disponível em: https://karger.com/article/doi/10.1159/000441066. Acesso em: 30 ago. 2025.

WANG, Hong-Xing; WANG, Yu-Ping. Gut Microbiota-brain Axis. Chinese Medical Journal, v. 129, n. 19, p. 2373-2380, out. 2016. Disponível em: https://doi.org/10.4103/0366-6999.190667. Acesso em: 13 mar. 2025.

XU, Congmin; ZHU, Huaiqiu; QIU, Peng. Aging progression of human gut microbiota. BMC Microbiology, v. 19, n. 1, 28 out. 2019. Disponível em: https://doi.org/10.1186/s12866-019-1616-2. Acesso em: 23 mar. 2025.

YANG, Jianshe et al. The Gut Microbiota Modulates Neuroinflammation in Alzheimer's Disease: Elucidating Crucial Factors and Mechanistic Underpinnings. CNS Neuroscience & Therapeutics, v. 30, n. 10, out. 2024. Disponível em: https://doi.org/10.1111/cns.70091. Acesso em: 13 mar. 2025.

YANG, Xueqin; YU, Dongke; XUE, Li; et al. Probiotics modulate the microbiota–gut–brain axis and improve memory deficits in aged SAMP8 mice. Acta Pharmaceutica Sinica B, v. 10, n. 3, p. 475–487, 2020. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S221138351831030X. Acesso em: 29 ago. 2025.

YAO, Mingfei; XIE, Jiaojiao; DU, Hengjun; et al. Progress in microencapsulation of probiotics: A review. Comprehensive Reviews in Food Science and Food Safety, v. 19, n. 2, p. 857–874, 2020. Disponível em: https://ift.onlinelibrary.wiley.com/doi/10.1111/1541-4337.12532. Acesso em: 29 ago. 2025.

YU, Alvin; LAU, Albert Y. Glutamate and Glycine Binding to the NMDA Receptor. Structure (London, England: 1993), v. 26, n. 7, p. 1035-1043.e2, 2018. Disponível em: DOI: 10.1016/j.str.2018.05.004. Acesso em: 29 ago. 2025.

YUE, Qian; LENG, Xinyue; XIE, Ningqing; et al. Endothelial Dysfunctions in Blood–Brain Barrier Breakdown in Alzheimer’s Disease: From Mechanisms to Potential Therapies. CNS Neuroscience & Therapeutics, v. 30, n. 11, p. e70079, 2024. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/cns.70079. Acesso em: 30 ago. 2025.

ZHANG, Jingjing; KONG, Guoqing; YANG, Jinyue; et al. Pathological mechanisms and treatment progression of Alzheimer’s disease. European Journal of Medical Research, v. 30, n. 1, p. 625, 2025. Disponível em: https://doi.org/10.1186/s40001-025-02886-9. Acesso em: 29 ago. 2025.

ZHUANG, Zhen-Qian; SHEN, Lin-Lin; LI, Wei-Wei; et al. Gut Microbiota is Altered in Patients with Alzheimer’s Disease. Journal of Alzheimer’s Disease, v. 63, n. 4, p. 1337–1346, 2018. Disponível em: https://journals.sagepub.com/doi/full/10.3233/JAD-180176. Acesso em: 30 ago. 2025.

ZOU, Dajiang; LIU, Renzheng; LV, Yangjing; et al. Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, v. 38, n. 1, p. 2270781, 2023. Disponível em: https://www.tandfonline.com/doi/10.1080/14756366.2023.2270781?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. Acesso em: 30 ago. 2025.

Downloads

Publicado

2025-09-28

Edição

Seção

Artigos

Como Citar

EFEITO DOS PROBIÓTICOS SOBRE AS FUNÇÕES COGNITIVAS E MNEMÔNICAS DE PACIENTES COM DOENÇA DE ALZHEIMER. (2025). ERR01, 10(4), e8497. https://doi.org/10.56238/ERR01v10n4-046